Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Vetter, a globally operating CDMO, has completed several important steps in the ongoing development and upcoming launch of V-OVS® next.
Clinical trials continue to be a driving force in ophthalmology, propelling the development of innovative treatments and ...
Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback